System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Yu Sunakawa is an expert in Oncology at St. Marianna Medical University Hospital (Japan). As of October 2026, ScienceLeadR ranks Yu Sunakawa in the top 1% of experts worldwide for Gastrointestinal Neoplasms, Rectal Diseases and Intestinal Neoplasms. Yu Sunakawa has authored 380 publications, the most recent in 2026, and is an investigator in 11 clinical trials, 1 of them ongoing. SLR score: 1,699 (community average: 125). How the SLR is computed.

LeadR Profile

Yu Sunakawa St. Marianna Medical University Hospital Japan
1 699 ScienceLeadR Reputation 1699

Unlock

Register Login
Network Map

Oncology

Subspecialties: Biochemistry - Gastroenterology - Genetics

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2010 - 2026
Source: PubMed

St. Marianna University School of Medicine

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 380

Citations

Citations: 3 160 1st author: 78 Last author: 49 Unique author: 5

Main journals

J Clin Oncol 123
Ann Oncol 77
Target Oncol 11
ESMO Open 8
Eur J Cancer 8

Best Journals

J Clin Oncol 64
Ann Oncol 50
N Engl J Med 4

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
A prospective study evaluating the impact of waiting time on blood testing and clinical workflows in cancer patients.
PMID 42892660 — travel, research design, blood, workflow, neoplasms, drug therapy, prospective studies, chemotherapy		Int J Clin Oncol20260
Anti-EGFR antibody therapy and skin toxicity: Retrospective analysis and role of pharmacists in protocol-based pharmacotherapy management.
PMID 42788290 — skin, biopharmaceutics, antibodies, neoplasms, pharmacists, prescriptions, drug therapy, physicians, pharmacology, clinical, therapeutics, colorectal neoplasms, dermatology		Int J Clin Pharmacol Ther20260
Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial.
PMID 42659588 — cetuximab, neoplasms, bevacizumab, fluorouracil, colorectal neoplasms		J Clin Oncol Top journal20260
Prognostic impact of circulating tumor RAS and BRAF mutation dynamics in patients with metastatic colorectal cancer.
PMID 42633244 — oncogenes, neoplasms, sarcoma, therapeutics, colorectal neoplasms, tissues, mutation		iScience20260
Chemotherapy After Colonic Stent in Patients With Unresectable Obstructive Colorectal Cancer: A Retrospective Multicenter Observational Study.
PMID 42592288 — bias, stents, neoplasms, drug therapy, colorectal neoplasms, chemotherapy		Endosc Int Open20260

Clinical Studies 11

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 1 4
Phase 3 4
Phase 2 2
Phase 1/Phase 2 1

By status:

Completed 8
Active not recruiting 3

By type:

Interventional 11

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 4
multicentric5to9 0
multicentricup10 7

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
NCT04579380 — cells, biliary tract neoplasms, fulvestrant, lung, muscles, breast neoplasms, genetics, pharmaceutical preparations, uterine cervical neoplasms, neoplasms, carcinoma, non-small-cell lung, urologic neoplasms, hormones, lung neoplasms, small cell lung carcinoma, breast, biliary tract, uterine neoplasms, colorectal neoplasms, veins, mutation, trastuzumab, her2 mutation, carcinoma		Phase 2Active not recruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS